Unnamed: 0,title,date,stock,sentiment
684843.0,"Intra-Cellular Therapies Q1 EPS $(0.730) Beats $(0.930) Estimate, Sales $1.083M Miss $1.440M Estimate",2020-05-07 08:12:00-04:00,ITCI,negative
684844.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,ITCI,negative
684845.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ITCI,neutral
684846.0,Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.,2020-04-08 09:34:00-04:00,ITCI,positive
684847.0,Intra-Cellular Reports Initiation Of Promotional Activities For CAPLYTA For Treatment Of Schizophrenia In Adults,2020-04-02 08:21:00-04:00,ITCI,neutral
684848.0,Intra-Cellular Therapies Initiates Promotional Activities For CAPLYTA For The Treatment Of Schizophrenia In Adults,2020-04-02 08:08:00-04:00,ITCI,neutral
684849.0,Intra-Cellular Therapies Announces Availability of CAPLYTA for Adult Patients with Schizophrenia,2020-03-23 07:33:00-04:00,ITCI,neutral
684850.0,10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades,2020-03-17 17:13:00-04:00,ITCI,neutral
684851.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,ITCI,negative
684852.0,"BTIG Research Maintains Buy on Intra-Cellular Therapies, Lowers Price Target to $68",2020-03-03 07:52:00-05:00,ITCI,negative
684853.0,"Intra-Cellular Therapies Q4 EPS $(0.74) Beats $(0.81) Estimate, Sales $60.613K",2020-03-02 07:32:00-05:00,ITCI,neutral
684854.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,ITCI,neutral
684855.0,Intra-Cellular Therapies Highlights Data From Pivotal Study Of CAPLYTA For Treatment Of Schizophrenia In Adults Published In JAMA Psychiatry,2020-02-20 17:03:00-05:00,ITCI,neutral
684856.0,Evercore ISI Group Initiates Coverage On Intra-Cellular Therapies with Outperform Rating,2020-02-20 05:21:00-05:00,ITCI,neutral
684857.0,10 Biggest Price Target Changes For Tuesday,2020-02-18 08:35:00-05:00,ITCI,neutral
684858.0,"Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Raises Price Target to $47",2020-02-18 06:57:00-05:00,ITCI,negative
684859.0,Intra-Cellular Therapies shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral.,2020-01-31 08:23:00-05:00,ITCI,neutral
684860.0,"JP Morgan Downgrades Intra-Cellular Therapies to Neutral, Raises Price Target to $26",2020-01-31 06:35:00-05:00,ITCI,positive
684861.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,ITCI,neutral
684862.0,54 Biggest Movers From Yesterday,2020-01-09 04:47:00-05:00,ITCI,neutral
684863.0,40 Stocks Moving In Wednesday's Mid-Day Session,2020-01-08 12:15:00-05:00,ITCI,neutral
684864.0,Intra-Cellular Therapies shares are trading lower after the company priced its 10 million share public offering of common stock at $29.50 per share.,2020-01-08 08:43:00-05:00,ITCI,positive
684865.0,50 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-08 08:31:00-05:00,ITCI,neutral
684866.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,ITCI,positive
684867.0,Intra-Cellular Therapies Prices 10M Share Public Offering of Common Stock @$29.50/Share,2020-01-07 21:52:00-05:00,ITCI,positive
684868.0,"The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering",2020-01-07 07:57:00-05:00,ITCI,negative
684869.0,15 Stocks Moving in Tuesday's Pre-Market Session,2020-01-07 07:48:00-05:00,ITCI,neutral
684870.0,A Peek Into The Markets: US Stock Futures Up Ahead Of Economic Data,2020-01-07 07:31:00-05:00,ITCI,neutral
684871.0,"5 Stocks To Watch For January 7, 2020",2020-01-07 04:14:00-05:00,ITCI,neutral
684872.0,"Intra-Cellular Therapies shares are trading lower after the company announced a proposed public offering of 10,000,000 shares of common stock.",2020-01-06 16:08:00-05:00,ITCI,positive
684873.0,Intra-Cellular Reports Commencement Of 10M Share Common Stock Offering,2020-01-06 16:06:00-05:00,ITCI,positive
684874.0,Intra-Cellular Therapies Files For Mixed Shelf Offering; Size Not Disclosed,2020-01-06 16:05:00-05:00,ITCI,neutral
684875.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,ITCI,neutral
684876.0,Intra-Cellular Therapies shares are trading lower. Not seeing any news to justify the price action. NOTE: Several stocks are trading on below-average volume due to the holidays.,2019-12-27 10:00:00-05:00,ITCI,positive
684877.0,"Canaccord Genuity Reiterates Buy on Intra-Cellular Therapies, Raises Price Target to $65",2019-12-24 10:20:00-05:00,ITCI,neutral
684878.0,"Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI",2019-12-24 08:13:00-05:00,ITCI,positive
684879.0,20 Stocks Moving in Tuesday's Pre-Market Session,2019-12-24 08:05:00-05:00,ITCI,neutral
684880.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,ITCI,negative
684881.0,Intra-Cellular Therapies shares are trading higher on continued momentum after the company announced it has received FDA approval for CAPLYTA for the treatment of schizophrenia in adults.,2019-12-24 07:11:00-05:00,ITCI,positive
684882.0,78 Biggest Movers From Yesterday,2019-12-24 04:32:00-05:00,ITCI,neutral
684883.0,Mid-Afternoon Market Update: Dow Rises 110 Points; Intra-Cellular Therapies Shares Spike Higher,2019-12-23 14:05:00-05:00,ITCI,positive
684884.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-23 12:19:00-05:00,ITCI,neutral
684885.0,Mid-Day Market Update: Cincinnati Bell Jumps Following Acquisition News; Safe-T Group Shares Plunge,2019-12-23 12:13:00-05:00,ITCI,positive
684886.0,Intra-Cellular Therapies Soars To Multiyear High Following FDA Nod For Schizophrenia Drug,2019-12-23 11:09:00-05:00,ITCI,neutral
684887.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,ITCI,neutral
684888.0,Mid-Morning Market Update: Markets Open Higher; Culligan To Acquire AquaVenture For $27.10/Share,2019-12-23 10:14:00-05:00,ITCI,neutral
684889.0,Intra-Cellular Therapies Option Alert: Jan 17 $15 Calls Sweep (2) near the Ask: 1500 @ $11.35 vs 24600 OI; Ref=$25.69,2019-12-23 09:54:00-05:00,ITCI,positive
684890.0,16 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-23 07:50:00-05:00,ITCI,neutral
684891.0,Intra-Cellular Therapies shares are trading higher after the company announced it has received FDA approval for CAPLYTA for the treatment of schizophrenia in adults.,2019-12-23 07:33:00-05:00,ITCI,positive
684892.0,Intra-Cellular Therapies' CAPLYTA Approved by the FDA for the Treatment of Schizophrenia in Adults,2019-12-23 07:00:00-05:00,ITCI,positive
684893.0,"The Week Ahead In Biotech: Correvio, Intra-Cellular Therapies Await FDA Decisions",2019-12-22 12:08:00-05:00,ITCI,positive
684894.0,Intra-Cellular Therapies Option Alert: Dec 20 $15 Calls at the Ask: 1495 @ $0.801 vs 3582 OI; Ref=$12.7,2019-12-12 14:50:00-05:00,ITCI,positive
684895.0,Intra-Cellular Therapies Highlights Lumateperone Presentations At Meeting Of American College Of Neuropsychopharmacology,2019-12-12 07:31:00-05:00,ITCI,neutral
684896.0,41 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-10 08:10:00-05:00,ITCI,neutral
684897.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,ITCI,neutral
684898.0,Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates,2019-11-29 08:13:00-05:00,ITCI,neutral
684899.0,36 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-25 08:40:00-05:00,ITCI,neutral
684900.0,Intra-Cellular Therapies Q3 EPS $(0.63) Up From $(0.76) YoY,2019-11-05 07:48:00-05:00,ITCI,neutral
684901.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,ITCI,negative
684902.0,46 Biggest Movers From Yesterday,2019-10-03 05:05:00-04:00,ITCI,neutral
684903.0,Intra-Cellular Therapies shares are trading higher on a potential rebound after the stock dropped more than 10% yesterday.,2019-10-02 14:48:00-04:00,ITCI,positive
684904.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,ITCI,positive
684905.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,ITCI,negative
684906.0,"Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.",2019-10-01 13:02:00-04:00,ITCI,negative
684907.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,ITCI,negative
684908.0,Stocks That Hit 52-Week Lows On Monday,2019-09-30 11:20:00-04:00,ITCI,negative
684909.0,Intra-Cellular Therapies shares are trading lower after the company filed for a common stock offering up to $75 million.,2019-09-13 10:43:00-04:00,ITCI,neutral
684910.0,Intra-Cellular Therapies Files For Up To $75M Common Stock Offering,2019-09-12 17:10:00-04:00,ITCI,neutral
684911.0,"Intra-Cellular Therapies Director Alafi Buys 485,000 @ Avg Price: $10.26",2019-09-11 16:37:00-04:00,ITCI,neutral
684912.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-09-10 12:19:00-04:00,ITCI,neutral
684913.0,FDA: No Adcom Meeting For Intra-Cellular's Schizophrenia Drug,2019-09-10 11:33:00-04:00,ITCI,negative
684914.0,Mid-Morning Market Update: Markets Open Lower; HD Supply Posts Mixed Q2 Results,2019-09-10 10:24:00-04:00,ITCI,negative
684915.0,22 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-10 09:02:00-04:00,ITCI,neutral
684916.0,Intra-Cellular Therapies shares are trading lower after the company announced that the FDA has informed the company it does not plan on scheduling an advisory committee meeting in connection with its review of the company's NDA for Lumateperone.,2019-09-10 08:54:00-04:00,ITCI,neutral
684917.0,FDA Has Informed Intra-Cellular Therapies It Does Not Have Plans To Schedule An Advisory Committee Meeting In Connection With Review Of Co.'s New Drug Application For Lumateperone,2019-09-10 07:34:00-04:00,ITCI,neutral
684918.0,33 Stocks Moving in Friday's Pre-Market Session,2019-08-23 08:02:00-04:00,ITCI,neutral
684919.0,"Benzinga's Top Upgrades, Downgrades For August 12, 2019",2019-08-12 09:44:00-04:00,ITCI,positive
684920.0,"Jefferies Initiates Coverage On Intra-Cellular Therapies with Buy Rating, Announces $16 Price Target",2019-08-12 08:55:00-04:00,ITCI,neutral
684921.0,"JMP Securities Reiterates Market Outperform on Intra-Cellular Therapies, Lowers Price Target to $21",2019-08-08 08:07:00-04:00,ITCI,positive
684922.0,Intra-Cellular Therapies Q2 EPS $(0.68) Beats $(0.83) Estimate,2019-08-07 09:12:00-04:00,ITCI,neutral
684923.0,70 Biggest Movers From Yesterday,2019-08-06 04:46:00-04:00,ITCI,neutral
684924.0,45 Stocks Moving In Monday's Mid-Day Session,2019-08-05 12:37:00-04:00,ITCI,neutral
684925.0,Intra-Cellular Therapies shares are trading higher after the company announced it has reached an agreement to submit additional non-clinical information in connection with the FDA's ongoing review of the Company's New Drug application for lumateperone.,2019-08-05 10:49:00-04:00,ITCI,positive
684926.0,"Intra-Cellular Therapies Reached an Agreement with the FDA for the Submission of Additional Non-Clinical Information for NDA Review of Lumateperone, PDUFA Date Extended 3 Months to December 27, 2019",2019-08-05 07:45:00-04:00,ITCI,positive
684927.0,"A Look At Benzinga Pro's Most-Searched Tickers For July 24, 2019",2019-07-24 12:30:00-04:00,ITCI,neutral
684928.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., July 24, 2019",2019-07-24 11:36:00-04:00,ITCI,positive
684929.0,Intra-Cellular Therapies Option Alert: Aug 16 $10 Puts at the Bid: 500 @ $2.05 vs 14995 OI; Earnings 8/1 Before Open [est] Ref=$8.22,2019-07-24 09:38:00-04:00,ITCI,positive
684930.0,24 Stocks Moving In Wednesday's Pre-Market Session,2019-07-24 07:58:00-04:00,ITCI,neutral
684931.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,ITCI,neutral
684932.0,60 Biggest Movers From Yesterday,2019-07-24 04:57:00-04:00,ITCI,neutral
684933.0,"Intra-Cellular Therapies Says FDA Cancelled Meeting to Allow Sufficient Time to Review This New, Any Forthcoming Information as They Continue NDA Review",2019-07-23 19:41:00-04:00,ITCI,neutral
684934.0,STAT News Article Discusses FDA's Cancelling Of Advisory Committee Meeting To Review Intra-Cellular's Schizophrenia NDA,2019-07-23 15:23:00-04:00,ITCI,negative
684935.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,ITCI,neutral
684936.0,Intra-Cellular Therapies Resume Trade,2019-07-23 14:38:00-04:00,ITCI,neutral
684937.0,Intra-Cellular Therapies Option Alert: Aug 16 $7.5 Puts Sweep (17) above Ask!: 985 @ $0.439 vs 7285 OI; Earnings 8/1 Before Open [est] Ref=$9.1,2019-07-23 14:31:00-04:00,ITCI,positive
684938.0,"Intra-Cellular Therapies shares are trading lower after the FDA reported an advisory committee meeting with the company has been cancelled, citing 'new information' regarding the its NDA for its schizophrenia treatment.",2019-07-23 14:29:00-04:00,ITCI,negative
684939.0,Intra-Cellular Therapies Shares Resume Trade,2019-07-23 14:28:00-04:00,ITCI,positive
684940.0,FDA Reports Psychopharmacologic Drugs Advisory Committee Meeting With Intra-Cellular Therapies Has Been Cancelled Because Of New Information Regarding Application,2019-07-23 14:23:00-04:00,ITCI,negative
684941.0,Intra-Cellular Therapies Option Alert: Aug 16 $15 Calls Sweep (18) near the Ask: 500 @ $0.85 vs 8990 OI; Earnings 8/1 Before Open [est] Ref=$11.29,2019-07-23 14:21:00-04:00,ITCI,positive
684942.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,ITCI,negative
684943.0,"A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019",2019-07-09 11:10:00-04:00,ITCI,neutral
684944.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, July 9, 2019",2019-07-09 09:49:00-04:00,ITCI,positive
684945.0,52 Biggest Movers From Yesterday,2019-07-09 04:59:00-04:00,ITCI,neutral
684946.0,Mid-Afternoon Market Update: Dow Down 150 Points; Intra-Cellular Therapies Shares Plunge,2019-07-08 14:37:00-04:00,ITCI,positive
684947.0,"A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019",2019-07-08 13:50:00-04:00,ITCI,neutral
684948.0,36 Stocks Moving In Monday's Mid-Day Session,2019-07-08 12:50:00-04:00,ITCI,neutral
684949.0,Mid-Day Market Update: Crude Oil Up Over 1%; Sol-Gel Technologies Shares Spike Higher,2019-07-08 12:21:00-04:00,ITCI,negative
684950.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, July 8, 2019",2019-07-08 10:28:00-04:00,ITCI,positive
684951.0,Mid-Morning Market Update: Markets Open Lower; Deutsche Bank To Cut 18K Jobs,2019-07-08 10:20:00-04:00,ITCI,negative
684952.0,What Caused The Opening Gap In Intra-Cellular Therapies?,2019-07-08 10:13:00-04:00,ITCI,neutral
684953.0,Intra-Celluar Therapies Falls Following Results For Treatment Of Bipolar Depression,2019-07-08 08:52:00-04:00,ITCI,negative
684954.0,Intra-Cellular Therapies shares are trading lower after the company said its 401 Study of Lumateperone did not meet its primary endpoint.,2019-07-08 08:49:00-04:00,ITCI,neutral
684955.0,Intra-Celluar Therapies Shares Resume Trading Higher After Announcing Mixed Study Results,2019-07-08 07:30:00-04:00,ITCI,positive
684956.0,Intra-Cellular Therapies Says Study 401 of Lumateperone Did not Meet its Primary Endpoint,2019-07-08 07:07:00-04:00,ITCI,neutral
684957.0,Intra-Cellular Therapies' Phase 3 404 Trial of Lumateperone Met its Primary and Key Secondary Endpoints,2019-07-08 07:03:00-04:00,ITCI,neutral
684958.0,"Intra-Cellular Therapies Halted, News Pending",2019-07-08 06:59:00-04:00,ITCI,neutral
684959.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings",2019-07-06 14:45:00-04:00,ITCI,neutral
684960.0,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,2019-07-01 07:14:00-04:00,ITCI,neutral
684961.0,60 Biggest Movers From Yesterday,2019-06-18 04:54:00-04:00,ITCI,neutral
684962.0,44 Stocks Moving In Monday's Mid-Day Session,2019-06-17 12:23:00-04:00,ITCI,neutral
684963.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,ITCI,positive
684964.0,"Intra-Cellular Therapies shares are trading higher after the FDA announced a Psychopharmacologic Drugs Advisory Committee meeting on July 31, 2019 to discuss the NDA for lumateperone.",2019-06-13 15:02:00-04:00,ITCI,positive
684965.0,"UPDATE: Intra-Cellular Says Sees PDUFA Date For Lumateperone Sep. 27, 2019",2019-06-13 09:05:00-04:00,ITCI,neutral
684966.0,Intra-Cellular Therapies Reports FDA Advisory Committee Meeting To Review New Drug Application For Lumateperone For Treatment Of Schizophrenia In Adults,2019-06-13 08:57:00-04:00,ITCI,neutral
684967.0,30 Stocks Moving In Thursday's Pre-Market Session,2019-06-13 08:22:00-04:00,ITCI,neutral
684968.0,50 Biggest Movers From Yesterday,2019-06-13 05:44:00-04:00,ITCI,neutral
684969.0,Intra-Cellular Therapies Option Alert: Fri $10 Puts at the Bid: 8000 @ $0.051 vs 21564 OI; Ref=$12.67,2019-05-16 09:47:00-04:00,ITCI,positive
684970.0,Intra-Cellular Therapies Inc. Q1 EPS $(0.63) Beats $(0.87) Estimate,2019-05-08 07:34:00-04:00,ITCI,neutral
684971.0,Intra-Cellular Therapies Presents Additional Results From its Open Label Safety Study of Lumateperone,2019-04-15 07:05:00-04:00,ITCI,positive
684972.0,"Watching Stocks With Alzheimer's Treatment Candidates: Merck, Roche, AbbVie, Neurotrope, AC Immune, Denali, INmune Bio, BioXcel Therapeutics, Intra-Cellular, Anavex, Pain Therapeutics, Grifols",2019-03-21 07:37:00-04:00,ITCI,negative
684973.0,Intra-Cellular Therapies Inc. Q4 EPS $(0.75) Beats $(0.91) Estimate,2019-02-27 07:41:00-05:00,ITCI,neutral
684974.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,ITCI,neutral
684975.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,ITCI,positive
684976.0,Intra-Cellular Therapies shares are trading lower after the company said it will not proceed with its Study 201 due to the expectation it would not meet its primary endpoint.,2018-12-18 09:08:00-05:00,ITCI,neutral
684977.0,Intra-Cellular Therapies To Discontinue Study 201 In Alzheimer's Treatment After A Data Monitoring Committee Determined The Study Was Unlikely To Meet Its Primary Endpoint,2018-12-18 08:34:00-05:00,ITCI,positive
684978.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,ITCI,positive
684979.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,ITCI,negative
684980.0,"Intra-Cellular Therapies Shares Tick Higher On Heavy Volume As Traders Circulate Price Target Raise To New Street High By RBC, Now At $37",2018-12-12 11:28:00-05:00,ITCI,positive
684981.0,Intra-Cellular Therapies Highlights Will Present Long-Term Data From Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia At American College of Neuropsychopharmacology,2018-12-11 17:34:00-05:00,ITCI,positive
684982.0,34 Stocks Moving In Tuesday's Mid-Day Session,2018-12-11 12:29:00-05:00,ITCI,neutral
684983.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,ITCI,neutral
684984.0,22 Stocks Moving In Tuesday's Pre-Market Session,2018-12-11 08:03:00-05:00,ITCI,neutral
684985.0,Intra-Cellular Therapies Announces FDA Acceptance Of New Drug Application For Lumateperone For The Treatment Of Schizophrenia,2018-12-11 07:13:00-05:00,ITCI,positive
684986.0,48 Biggest Movers From Friday,2018-12-10 05:23:00-05:00,ITCI,neutral
684987.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,ITCI,neutral
684988.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:21:00-05:00,ITCI,negative
684989.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,ITCI,negative
684990.0,"Leerink Swann Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces $27 Price Target",2018-11-15 09:18:00-05:00,ITCI,neutral
684991.0,76 Biggest Movers From Yesterday,2018-11-15 04:20:00-05:00,ITCI,neutral
684992.0,58 Stocks Moving In Wednesday's Mid-Day Session,2018-11-14 12:49:00-05:00,ITCI,neutral
684993.0,"Leerink Swann Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces $27 Price Target",2018-11-13 08:31:00-05:00,ITCI,neutral
684994.0,Intra-Cellular Therapies Inc. - Common Stock Q3 EPS $(0.76) Beats $(0.84) Estimate,2018-11-07 08:23:00-05:00,ITCI,neutral
684995.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,ITCI,negative
684996.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,ITCI,neutral
684997.0,Intra-Cellular Therapies Reports Favorable Safety Profile For ITI-214 In A Phase 1/2 Clinical Trial In Patients With Parkinson's Disease,2018-10-23 07:10:00-04:00,ITCI,positive
684998.0,"Benzinga's Week Ahead: Can Tech Earnings Restore The Rally? Amazon, Google To Report",2018-10-22 12:49:00-04:00,ITCI,positive
684999.0,"REMINDER: ESMO 2018 Event Continues Today, Clinical Updates Presented Today Include: CytomX Therapeutics, Mirati Therapeutics, Merck, NuCana, Protagonist Therapeutics, SELLAS Life Sciences, Epizyme, Kura Oncology, Intra-Cellular Therapies, and AVEO Pharma",2018-10-22 05:56:00-04:00,ITCI,neutral
685000.0,Intra-Cellular Therapies To Present Top-Line Results From ITI-214 Phase 1/2 Clinical Trial In Patients With Parkinson's Disease At 2018 American Neurological Association Annual Meeting. Oct. 21-24,2018-10-17 08:04:00-04:00,ITCI,neutral
685001.0,Intra-Cellular Therapies Reports Completion Of Submission Of New Drug Application For Lumateperone For Treatment Of Schizophrenia,2018-09-28 07:08:00-04:00,ITCI,neutral
685002.0,"Cantor Fitzgerald Initiates Coverage On Intra-Cellular Therapies with Overweight Rating, Announces $32 Price Target",2018-08-23 07:08:00-04:00,ITCI,negative
685003.0,Intra-Cellular Therapies Inc. Q2 EPS $(0.68) Beats $(0.76) Estimate,2018-08-02 09:40:00-04:00,ITCI,neutral
685004.0,Intra-Cellular Therapies Announces Publication Highlighting ITI-214 Mechanism of Action and Describing Results in Preclinical Models of Heart Failure,2018-07-23 07:12:00-04:00,ITCI,negative
685005.0,Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus,2018-07-21 08:44:00-04:00,ITCI,neutral
685006.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,ITCI,neutral
685007.0,Intra-Cellular Therapies Reports Initiation Of Rolling Submission Of NDA For Lumateperone For Treatment Of Schizophrenia,2018-06-06 07:03:00-04:00,ITCI,neutral
685008.0,Intra-Cellular Therapies Inc. - Common Stock Q1 EPS $(0.65) Beats $(0.66) Estimate,2018-05-03 07:14:00-04:00,ITCI,neutral
685009.0,"Benzinga's Daily Biotech Pulse: Intra-cellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences",2018-04-27 07:25:00-04:00,ITCI,neutral
685010.0,41 Biggest Movers From Yesterday,2018-04-03 04:18:00-04:00,ITCI,neutral
685011.0,33 Stocks Moving In Monday's Mid-Day Session,2018-04-02 12:53:00-04:00,ITCI,neutral
685012.0,"Intra-Cellular Therapies Shares Down 15.7% In Sympathy With Alkermes After FDA Refuses To Review ALKS-5461; Earlier, Stat News' Adam F Tweeted: 'Anyone confident in $ITCI now? I wouldn't be.'",2018-04-02 11:07:00-04:00,ITCI,positive
685013.0,28 Stocks Moving In Monday's Pre-Market Session,2018-04-02 08:00:00-04:00,ITCI,neutral
685014.0,35 Stocks Moving In Tuesday's Mid-Day Session,2018-03-13 12:28:00-04:00,ITCI,neutral
685015.0,Intra-Cellular Therapies Announces 'Positive' Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia,2018-03-13 07:32:00-04:00,ITCI,neutral
685016.0,42 Biggest Movers From Friday,2018-03-05 05:08:00-05:00,ITCI,neutral
685017.0,Intra-Cellular Therapies Reports Q4 EPS $(0.56) vs $(0.54) Est.,2018-03-01 07:21:00-05:00,ITCI,neutral
685018.0,"JP Morgan Initiates Coverage On Intra-Cellular Therapies with Overweight Rating, Announces $25.00 Price Target",2018-02-26 09:13:00-05:00,ITCI,neutral
685019.0,"RBC Capital Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces $33.00 Price Target",2018-02-08 09:14:00-05:00,ITCI,neutral
685020.0,"Benzinga's Top Upgrades, Downgrades For December 15, 2017",2017-12-15 08:57:00-05:00,ITCI,positive
685021.0,"Canaccord Genuity Initiates Coverage On Intra-Cellular Therapies with Buy Rating, Announces $31.00 Price Target",2017-12-15 08:32:00-05:00,ITCI,neutral
685022.0,"Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of Neuropsychopharmacology",2017-12-07 10:03:00-05:00,ITCI,neutral
685023.0,35 Biggest Movers From Yesterday,2017-11-21 05:10:00-05:00,ITCI,neutral
685024.0,32 Stocks Moving In Monday's Mid-Day Session,2017-11-20 12:30:00-05:00,ITCI,neutral
685025.0,28 Stocks Moving In Monday's Pre-Market Session,2017-11-20 08:06:00-05:00,ITCI,neutral
685026.0,Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia,2017-11-20 07:07:00-05:00,ITCI,neutral
685027.0,SunTrust Robinson Humphrey Upgrades Intra-Cellular Therapies to Buy,2017-11-08 09:59:00-05:00,ITCI,neutral
685028.0,"Intra-Cellular Therapies Reports Q3 EPS $(0.53) vs $(0.62) Est., Sales $30.754K vs $60K Est.",2017-11-08 07:45:00-05:00,ITCI,neutral
685029.0,Intra-Cellular Therapies Reports Commencement Of Enrollment Of Trial Evaluating ITI-214 In Patients With Parkinson's Disease,2017-10-03 08:08:00-04:00,ITCI,neutral
685030.0,Intra-Cellular Therapies Prices ~9.67M Share Offering @$15.50/Share,2017-09-28 04:36:00-04:00,ITCI,positive
685031.0,Intra-Cellular Reports Commencement Of $150M Share Common Stock Offering,2017-09-26 16:02:00-04:00,ITCI,positive
685032.0,15 Biggest Mid-Day Gainers For Thursday,2017-09-07 12:30:00-04:00,ITCI,neutral
685033.0,Intra-Cellular Therapies Reports Topline Data Form First Part Of Open-Label Safety Switching Study Showed No Dose Titration Of Lumateperone Required For 6-Week Treatment Duration,2017-09-07 07:16:00-04:00,ITCI,positive
685034.0,15 Biggest Mid-Day Gainers For Wednesday,2017-08-30 12:34:00-04:00,ITCI,neutral
685035.0,Ladenburg Thalmann Upgrades Intra-Cellular Therapies to Buy,2017-08-30 10:08:00-04:00,ITCI,neutral
685036.0,"Benzinga's Top Upgrades, Downgrades For August 30, 2017",2017-08-30 09:17:00-04:00,ITCI,positive
685037.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-08-30 08:13:00-04:00,ITCI,neutral
685038.0,"Benzinga's Top Upgrades, Downgrades For August 24, 2017",2017-08-24 09:19:00-04:00,ITCI,positive
685039.0,JMP Securities Upgrades Intra-Cellular Therapies to Market Outperform,2017-08-24 07:07:00-04:00,ITCI,positive
685040.0,Mid-Afternoon Market Update: Crude Oil Up Over 1%; Express Shares Rise After Strong Q2 Results,2017-08-23 14:35:00-04:00,ITCI,positive
685041.0,15 Biggest Mid-Day Gainers For Wednesday,2017-08-23 12:18:00-04:00,ITCI,neutral
685042.0,Mid-Day Market Update: La-Z-Boy Drops After Q1 Miss; Paratek Pharmaceuticals Shares Rise,2017-08-23 12:09:00-04:00,ITCI,positive
685043.0,BB Biotech Reports 5.1% Stake In INtra-Cellular Therapies,2017-08-23 11:01:00-04:00,ITCI,neutral
685044.0,Mid-Morning Market Update: Markets Open Lower; Lowe's Earnings Miss Expectations,2017-08-23 10:14:00-04:00,ITCI,negative
685045.0,"Intra-Cellular Therapies Reports  FDA Informed Co. That Data on lumateperone To Support Position That Metabolic Pathway In Animals Are Different Than Humans, Which Indicates That Toxicity Observed In Animals Isn't Relevant To Humans",2017-08-23 08:02:00-04:00,ITCI,positive
685046.0,"Intra-Cellular Therapies Reports Q2 EPS $(0.41) vs $(0.74) Est., Sales $114.741K vs $30K Est.",2017-08-09 08:12:00-04:00,ITCI,neutral
685047.0,Benzinga's Option Alert Recap From July 12,2017-07-12 16:18:00-04:00,ITCI,positive
685048.0,Intracellular Therapies Option Alert: Aug 18 $10 Calls at the Ask: 900 @ $2.351 vs 387 OI; Ref=$11.85,2017-07-12 15:30:00-04:00,ITCI,positive
685049.0,22 Stocks Moving In Friday's Pre-Market Session,2017-05-12 08:03:00-04:00,ITCI,neutral
685050.0,Intra Cellular Therapies Pops to High of $10.15 on Volume,2017-05-10 12:59:00-04:00,ITCI,neutral
685051.0,Intra-Cellular Therapies Reports Q1 EPS $(0.62) vs $(0.72) Est.,2017-05-10 07:46:00-04:00,ITCI,neutral
685052.0,Intra-Cellular Therapies Presents Data 'Supporting' the Potential for Potent and Rapid Antidepressant Activity with Lumateperone,2017-05-08 07:21:00-04:00,ITCI,neutral
685053.0,18 Biggest Mid-Day Losers For Tuesday,2017-05-02 13:10:00-04:00,ITCI,negative
685054.0,5 Biggest Price Target Changes For Tuesday,2017-05-02 09:46:00-04:00,ITCI,neutral
685055.0,"Benzinga's Top Upgrades, Downgrades For May 2, 2017",2017-05-02 09:21:00-04:00,ITCI,positive
685056.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-05-02 08:05:00-04:00,ITCI,neutral
685057.0,Leerink Swann Downgrades Intra-Cellular Therapies to Market Perform,2017-05-02 07:12:00-04:00,ITCI,neutral
685058.0,Ladenburg Thalmann Downgrades Intra-Cellular Therapies to Neutral,2017-05-02 07:11:00-04:00,ITCI,neutral
685059.0,15 Biggest Mid-Day Losers For Monday,2017-05-01 13:05:00-04:00,ITCI,negative
685060.0,"PiperJaffray Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $10.00",2017-05-01 10:58:00-04:00,ITCI,negative
685061.0,Mid-Morning Market Update: Markets Mostly Higher; DISH Network Profit Tops Estimates,2017-05-01 10:10:00-04:00,ITCI,positive
685062.0,15 Stocks Moving In Monday's Pre-Market Session,2017-05-01 08:10:00-04:00,ITCI,neutral
685063.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,ITCI,neutral
685064.0,25 Biggest Mid-Day Gainers For Thursday,2017-03-02 12:39:00-05:00,ITCI,neutral
685065.0,IntraCellular Pops to High of $13.41 on Volume,2017-03-01 10:09:00-05:00,ITCI,neutral
685066.0,"Intra-Cellular Reports Q4 EPS $(0.64) vs $(0.77) Est., Sales $97.895K vs $20K Est.",2017-03-01 07:17:00-05:00,ITCI,neutral
685067.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-12-22 08:31:00-05:00,ITCI,neutral
685068.0,Cantor Fitzgerald Initiates Coverage On Intra-Cellular Therapies at Overweight,2016-12-16 08:29:00-05:00,ITCI,negative
685069.0,"Intra-Cellular Therapies Shares Down 3.33% On Above Average Volume, Despite Filing After-Hours Wednesday Showing Alafi Capital Purchase Of 65K Shares",2016-12-08 12:45:00-05:00,ITCI,positive
685070.0,"Intra-Cellular Therapies, Inc.: Alafi Christopher D (Director, 10%+) Buys 65,000 @ Avg Price: $16.27 (Form4)",2016-12-07 16:35:00-05:00,ITCI,neutral
685071.0,8 Stocks That Rallied Three Days On Increasing Volume,2016-12-06 05:20:00-05:00,ITCI,neutral
685072.0,"Intra-Cellular Q3 EPS $(0.70) vs $(0.84) Est, Revenue $4.36K",2016-11-09 07:10:00-05:00,ITCI,neutral
685073.0,"Chipotle, Viacom And More: Fast Money Picks For October 3",2016-10-03 06:32:00-04:00,ITCI,neutral
685074.0,Technical Alert: Intra-Cellular Therapies Fails To Rebound After Crashing,2016-09-29 15:16:00-04:00,ITCI,negative
685075.0,Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher,2016-09-29 14:38:00-04:00,ITCI,positive
685076.0,12 Biggest Mid-Day Losers For Thursday,2016-09-29 13:10:00-04:00,ITCI,negative
685077.0,Mid-Day Market Update:  Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide,2016-09-29 12:25:00-04:00,ITCI,negative
685078.0,Stocks Hitting   52-Week Lows,2016-09-29 10:32:00-04:00,ITCI,negative
685079.0,Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations,2016-09-29 10:06:00-04:00,ITCI,negative
685080.0,7 Biggest Price Target Changes For Thursday,2016-09-29 09:23:00-04:00,ITCI,neutral
685081.0,Benzinga's Top Downgrades,2016-09-29 08:54:00-04:00,ITCI,positive
685082.0,15 Stocks Moving In Thursday's Pre-Market Session,2016-09-29 08:20:00-04:00,ITCI,neutral
685083.0,SunTrust Robinson Humphrey Downgrades Intra-Cellular Therapies to Neutral,2016-09-29 07:29:00-04:00,ITCI,neutral
685084.0,JMP Securities Downgrades Intra-Cellular Therapies to Market Perform,2016-09-29 06:13:00-04:00,ITCI,positive
685085.0,"4 After-Hours Movers: Earnings, FDA Trials & Guide-Downs",2016-09-28 17:28:00-04:00,ITCI,neutral
685086.0,Intra-Cellular Shares to Resume Trade at 4:30 p.m. EDT,2016-09-28 16:06:00-04:00,ITCI,positive
685087.0,"UPDATE: Intra-Cellular Says Active Control, Risperidone, Did Separate from Placebo; ITI-007 Statistically Significantly Better Than Risperidone on Key Safety, Tolerability Parameters",2016-09-28 16:03:00-04:00,ITCI,positive
685088.0,Intra-Cellular Therapeices Reports Top-Line Results from Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia: Neither Dose Separated from Placebo on Primary Endpoint,2016-09-28 16:02:00-04:00,ITCI,neutral
685089.0,ITI Shares Halted News Pending,2016-09-28 16:00:00-04:00,ITCI,positive
685090.0,Watch These 5 Huge Put Purchases In Monday Trade,2016-09-19 04:31:00-04:00,ITCI,positive
685091.0,Option Alert: ITCI Nov16 35.0 Puts: 900 @  ASK  $6.40: 1010 traded vs 73 OI:  Earnings 11/3  $44.42 Ref,2016-09-16 14:04:00-04:00,ITCI,positive
685092.0,"Intra-Cellular Therapies Reports Q2 EPS $(0.71) vs. Est. $(0.79), Rev. $228K vs. Est. $20K",2016-08-04 07:06:00-04:00,ITCI,neutral
685093.0,Intra-Cellular Reports Completion of Enrollment for ITI-007-302 Phase 3 Trial for Treatment of Schizophrenia,2016-06-30 07:01:00-04:00,ITCI,neutral
685094.0,Intra-Cellular Therapies Announces Initiation of ITI-007-201 Phase 3 Clinical Trial,2016-06-28 07:05:00-04:00,ITCI,neutral
685095.0,Option Alert: SWEEP (SELL) - ITCI Aug $45 Call - 1000 @ 3.25 in 4 orders. 1000 traded. OI: 738,2016-06-10 12:34:00-04:00,ITCI,positive
685096.0,"Piper Jaffray Initiates Coverage on Intra-Cellular Therapies at Overweight, Announces $57.00 PT",2016-06-02 09:03:00-04:00,ITCI,negative
685097.0,"Piper Jaffray Initiates Coverage on Intra-Cellular Therapies at Overweight, Announces $57.00 PT",2016-06-01 17:11:00-04:00,ITCI,negative
685098.0,Intra-Cellular Reports Q1 EPS $(0.64) vs $(0.78) Est.,2016-04-28 07:23:00-04:00,ITCI,neutral
685099.0,Intra-Cellular Therapies Presents Additional ITI-007 Data at SIRS Conference,2016-04-06 07:14:00-04:00,ITCI,neutral
685100.0,The Most Notable Insider Buys And Sells Of Last Week,2016-03-07 16:53:00-05:00,ITCI,neutral
685101.0,3 Biotech Companies With Recent Large Insider Buying,2016-03-02 07:31:00-05:00,ITCI,neutral
685102.0,Intra-Cellular Therapies Reports Q4 EPS $(0.67) vs. Est. $(0.90),2016-02-25 07:20:00-05:00,ITCI,neutral
685103.0,10 Stocks Moving On Friday's After-Hours Session,2016-01-17 17:52:00-05:00,ITCI,neutral
685104.0,12 Biotechs With Binary Events Coming This Year,2016-01-08 12:13:00-05:00,ITCI,neutral
685105.0,"Intra-Cellular Therapies Presents Additional Efficacy and Safety Data From the Positive Phase 3 Clinical Trial of ITI-007, Met Primary Endpoint Demonstrating Statistically Over Placebo",2015-12-09 16:02:00-05:00,ITCI,positive
685106.0,Intra-Cellular Therapies Announces Closing of $345 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares,2015-09-28 16:06:00-04:00,ITCI,positive
685107.0,Benzinga's Volume Movers,2015-09-23 10:24:00-04:00,ITCI,neutral
685108.0,"Intra-Cellular Therapies Reports Completion of Phase 1 Studies for ITI-214, a Phosphodiesterase Type 1 Inhibitor, and Assumes IND Sponsorship for ITI-214",2015-09-21 16:16:00-04:00,ITCI,negative
685109.0,"Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock, $300M",2015-09-21 16:01:00-04:00,ITCI,neutral
685110.0,Benzinga's Volume Movers,2015-09-17 10:39:00-04:00,ITCI,neutral
685111.0,Stocks Hitting 52-Week Highs,2015-09-17 10:16:00-04:00,ITCI,neutral
685112.0,Benzinga's Top #PreMarket Gainers,2015-09-17 08:10:00-04:00,ITCI,positive
685113.0,Mid-Afternoon Market Update: Cracker Barrel Drops Following Q4 Results; Intra-Cellular Therapies Shares Jump,2015-09-16 14:41:00-04:00,ITCI,positive
685114.0,Mid-Day Market Update: Crude Oil Surges Over 5%; Paycom Software Shares Tumble,2015-09-16 13:05:00-04:00,ITCI,negative
685115.0,Mid-Morning Market Update: Markets Mixed; FedEx Earnings Miss Estimates,2015-09-16 10:25:00-04:00,ITCI,negative
685116.0,Benzinga's Volume Movers,2015-09-16 10:20:00-04:00,ITCI,neutral
685117.0,Stocks Hitting 52-Week Highs,2015-09-16 10:10:00-04:00,ITCI,neutral
685118.0,Morning Market Gainers,2015-09-16 09:39:00-04:00,ITCI,neutral
685119.0,Benzinga's Top #PreMarket Gainers,2015-09-16 08:10:00-04:00,ITCI,positive
685120.0,Intra-Cellular Therapties +32% Following Announcement of Positive Top Line Results For ITI-007 First Phase 3 Trial,2015-09-16 07:04:00-04:00,ITCI,positive
685121.0,Intra-Cellular Therapties Announces Positive Top Line Results For ITI-007 First Phase 3 Trial,2015-09-16 06:03:00-04:00,ITCI,positive
685122.0,Intra-Cellular Therapies Reports Publication of Positive Phase 2 Schizophrenia Study in the Journal Biological Psychiatry,2015-09-01 16:09:00-04:00,ITCI,positive
685123.0,Little Bear Reports Intra-Cellular Therapies Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing,2015-07-15 20:31:00-04:00,ITCI,negative
685124.0,Intra-Cellular Therapies Initiates  Randomization for ITI-007-302 Phase 3 Trial in Schizophrenia,2015-06-23 08:02:00-04:00,ITCI,neutral
685125.0,SunTrust's 5 Biotech Picks For The Next 6 Months,2015-06-17 13:24:00-04:00,ITCI,neutral
685126.0,Intra-Cellular Therapies Reports Closing of Enrollment in ITI-007-301 Phase 3 Trial for Treatment of Schizophrenia Candidate,2015-06-15 08:02:00-04:00,ITCI,neutral
685127.0,Intra-Cellular Reported Will Further Analyze Phase 2 Trial of ITI-007 in Schizophrenia at Annual Meeting of APA,2015-05-18 07:16:00-04:00,ITCI,neutral
685128.0,Benzinga's Top Initiations,2015-05-06 09:32:00-04:00,ITCI,positive
685129.0,SunTrust Robinson Humphrey Initiates Intra-Cellular Therapies At Buy,2015-05-06 08:59:00-04:00,ITCI,neutral
685130.0,"SunTrust Robinson Humphrey Initiates Coverage on Intra-Cellular Therapies at Buy, Announces $50.00 PT",2015-05-06 06:53:00-04:00,ITCI,neutral
685131.0,"RBC Capital Initiates Coverage on Intra-Cellular Therapies at Outperform, Announces $41.00 PT",2015-04-14 05:59:00-04:00,ITCI,neutral
685132.0,Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program at the 15th International Congress on Schizophrenia Studies,2015-03-31 08:02:00-04:00,ITCI,neutral
685133.0,"Intra-Cellular Therapies Shareholder Sosland Buys 250,000 Shares @$24.00/Share -Form 4",2015-03-12 13:07:00-04:00,ITCI,positive
685134.0,"Intra-Cellular Reports Q4 EPS $(0.52) vs. Est. $(0.37), Rev. $65.8K vs. Est. $120K",2015-03-12 07:14:00-04:00,ITCI,neutral
685135.0,"US Stock Futures Mixed, All Eyes On Jobs Data",2015-03-06 07:37:00-05:00,ITCI,neutral
685136.0,Intra-Cellular Prices 4.75M Share Offering at $24.00/Share,2015-03-06 04:40:00-05:00,ITCI,positive
685137.0,Intra-Cellular Therapies Announces 4.25M Share Offering,2015-03-04 07:03:00-05:00,ITCI,positive
685138.0,UPDATE: JMP Securities Initiates Coverage On Intra-Cellular Therapies,2014-12-23 09:43:00-05:00,ITCI,positive
685139.0,"JMP Securities Initiates Coverage on Intra-Cellular Therapies at Market Outperform, Announces $26.00 PT",2014-12-23 08:53:00-05:00,ITCI,positive
685140.0,Intra-Cellular Therapies Announces Enrollment Of First Patient In Phase 3 Trial Of ITI-007,2014-11-25 08:08:00-05:00,ITCI,neutral
685141.0,Intra-Cellular Therapies Announces Additional Results From Phase I/II Clinical Trial for ITI-007,2014-11-21 08:32:00-05:00,ITCI,neutral
685142.0,Intra-Cellular Therapies and Takeda Announce Mutual Termination of Collaboration to Develop Phosphodiesterase (PDE1) Inhibitors for CNS Disorders ,2014-11-03 07:08:00-05:00,ITCI,negative
685143.0,US Stock Futures Signal Higher Start On Wall Street,2014-10-13 07:28:00-04:00,ITCI,neutral
685144.0,Intra-Cellular Therapies Announces Positive Topline Safety Results From Phase I/II Clinical Trial for ITI-007 ,2014-10-13 07:06:00-04:00,ITCI,positive
685145.0,Intra-Cellular Therapies To Present Results From Phase I/II Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia At The American Neurological Association 139th Annual Meeting,2014-10-06 16:31:00-04:00,ITCI,positive
685146.0,S-3 Filing from Intra-Cellular Thearpies Shows Registration for $150M Mixed Securities Shelf Offering,2014-08-29 16:31:00-04:00,ITCI,positive
685147.0,Intral-Cellular Therapies Reports Q2 EPS of $(0.15); Revenue of $219.24K,2014-08-12 07:33:00-04:00,ITCI,neutral
